TrialThe oncologist2025

Pemigatinib for previously treated metastatic or unresectable central nervous system tumors with fibroblast growth factor receptor mutations or rearrangements: FIGHT-207 results.

Iben Spanggaard et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.